Nanalysis to Present at December Investor Conferences

CALGARY, AB, Dec. 1, 2021 /CNW/ - Nanalysis Scientific Corp. ("Nanalysis", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) will be presenting at three upcoming investor conferences in December. We encourage shareholders to listen in and book meetings in order to stay up to date with our developments.

Nanalysis will join Chris Lahiji of LD Micro this morning Tuesday December 1, 2021 @11 am ET.
For more information, please click HERE.

Nanalysis will present to investors at SNN Canada Virtual Conference on Wednesday, December 8th, 2021 @12:00 pm ET.
For more information, please click HERE.

Nanalysis will present to investors at Sidoti December Virtual Micro Cap Conference on Thursday, December 9th, 2021 @10:45 am ET.
For more information, please click HERE.

Investors can register for a one-on-one meeting with either our CEO, Sean Krakiwsky or our CFO, Luke Caplette through either platform.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', Over the Counter (OTC) in the United States under the ticker symbol 'NSCIF', and on the Frankfurt Exchange (FRA) under the symbol '1N1'.

Nanalysis is an international business focused on capitalizing its proprietary technologies in nuclear magnetic resonance (NMR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).

Nanalysis Corp. is an industry leader in developing and manufacturing compact NMR spectrometers for laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology.

Through its European subsidiary RS2D, the Company's electronic boards and software are used in conventional NMR and MRI equipment and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.

To sign up for updates relating to Nanalysis, please complete the online form found HERE.

SOURCE Nanalysis Scientific Corp.

Matt Sellers, Investor Relations Manager, 587-436-1291, [email protected]; Matthew Selinger, Firm IR Group, 415-572-8152, [email protected]